Form 4 for RCUS Arcus Biosciences, Inc.
Accepted 2023-09-20 00:00:00 ET · period of report 2023-09-18 · accession 0001724521-23-000008 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-09-20 | 2023-09-18 | RCUS | Nuyten Dimitry SA | Chief Medical Off | D - Sale to Iss | $20.40 | -3,708 | 73.6K | -5% | -$75.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-18 | D | D | 3,708 | $20.40 | 73,591 | D | — | — | (F1) Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on January 15, 2021, and does not represent a discretionary trade by the reporting person. (F2) Includes 799 shares purchased on 5/31/2023 through the Company's Employee Stock Purchase Plan. |